TNDM vs. WRBY, LIVN, EYE, INSP, PRCT, AORT, LQDA, LMAT, ENOV, and CDRE
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include Warby Parker (WRBY), LivaNova (LIVN), National Vision (EYE), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Artivion (AORT), Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), Enovis (ENOV), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.
Tandem Diabetes Care vs. Its Competitors
Warby Parker (NYSE:WRBY) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.
93.2% of Warby Parker shares are owned by institutional investors. 18.2% of Warby Parker shares are owned by insiders. Comparatively, 1.9% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Warby Parker has higher earnings, but lower revenue than Tandem Diabetes Care. Warby Parker is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
Warby Parker has a net margin of -1.12% compared to Tandem Diabetes Care's net margin of -20.51%. Warby Parker's return on equity of -0.79% beat Tandem Diabetes Care's return on equity.
Warby Parker has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
In the previous week, Tandem Diabetes Care had 2 more articles in the media than Warby Parker. MarketBeat recorded 9 mentions for Tandem Diabetes Care and 7 mentions for Warby Parker. Warby Parker's average media sentiment score of 1.50 beat Tandem Diabetes Care's score of 0.64 indicating that Warby Parker is being referred to more favorably in the media.
Warby Parker currently has a consensus target price of $24.75, suggesting a potential downside of 1.57%. Tandem Diabetes Care has a consensus target price of $22.44, suggesting a potential upside of 50.00%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Warby Parker.
Summary
Warby Parker beats Tandem Diabetes Care on 12 of the 16 factors compared between the two stocks.
Get Tandem Diabetes Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tandem Diabetes Care Competitors List
Related Companies and Tools
This page (NASDAQ:TNDM) was last updated on 10/7/2025 by MarketBeat.com Staff
